Credit Suisse Ag Avadel Pharmaceuticals PLC Transaction History

Credit Suisse Ag

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 12, 2020	SELL	$3.34 - $7.7 $69,485 - $160,190	-20,804 Closed	0 $0
Q3 2019 Nov 12, 2019	SELL	$1.92 - $4.47 $59,458 - $138,426	-30,968 Reduced 59.82%	20,804 $87,000
Q2 2019 Aug 14, 2019	BUY	$1.09 - $3.19 $36,156 - $105,815	33,171 Added 178.33%	51,772 $150,000
Q1 2019 May 14, 2019	BUY	$1.44 - $3.29 $26,785 - $61,197	18,601 New	18,601 $27,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $626M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.